Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02680301 · ClinicalTrials.gov registry record · Phase 4

Topical Steroid Formulation and Wet Wraps

A Phase 4 study of Dermatitis, Atopic, sponsored by Seton Healthcare Family.

Completed
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT02680301: Completed Phase 4 study of Dermatitis, Atopic, sponsored by Seton Healthcare Family.

NCT02680301 is a Phase 4 study of Dermatitis, Atopic that has completed, run by Seton Healthcare Family. The registered enrollment target is 40 participants, below the 396-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02680301, a Phase 4 study of Dermatitis, Atopic, has completed, sponsored by Seton Healthcare Family.

COMPLETED
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to 1. Compare efficacy of 0.1% triamcinolone containing wet wrap as an ointment or as a cream formulation in patients with moderate to severe atopic dermatitis 2. The relative patient/subject acceptance and adherence will also be compared between the two wet wrap types

Primary Outcome

Change in atopic dermatitis based on physician global assessment scale: 0=clear; 1=almost clear; 2=mild disease; 3=moderate disease; 4=severe disease; 5- very severe disease Lower scores represent a better outcome.

Conditions Studied

Interventions

  • DRUG 0.1% triamcinolone CREAM
  • DRUG 0.1% triamcinolone OINTMENT

Study Locations (1)

Texas

  • Specially for Children Dermatology - Austin

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2016-03
Est. Completion 2018-06-01
Phase Phase 4
Seton Healthcare Family

15 total trials

What the finished NCT02680301 record still lists

NCT02680301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 396-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 2 interventions - of which 0.1% triamcinolone CREAM is the first listed.

NCT02680301 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT02680301 about?

NCT02680301 is a clinical study titled "Topical Steroid Formulation and Wet Wraps". The purpose of this study is to 1. Compare efficacy of 0.1% triamcinolone containing wet wrap as an ointment or as a cream formulation in patients with moderate to severe atopic dermatitis 2. The relative patient/subject acceptance and adherence will also be compared between the two wet wrap types

What is the current status of trial NCT02680301?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2016-03. Estimated completion is 2018-06-01.

What conditions does trial NCT02680301 study?

This clinical trial studies the following conditions: Dermatitis, Atopic.

What interventions are being tested in trial NCT02680301?

The interventions under investigation include: 0.1% triamcinolone CREAM (DRUG), 0.1% triamcinolone OINTMENT (DRUG).

Who is sponsoring clinical trial NCT02680301?

This trial is sponsored by Seton Healthcare Family, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02680301 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dermatitis, Atopic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02680301's enrollment target sits among peer trials

40 27th of 29 higher than 3 of 29 other Dermatitis, Atopic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Dermatitis, Atopic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02680301, the US trial registry maintained by the National Library of Medicine. NCT02680301 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.